Teet Pullerits
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Teet Pullerits has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Jan Lötvall
University of Gothenburg Gothenburg Sweden
6 shared publications - Bright Ibeabughichi Nwaru
University of Gothenburg, Gothenbburg, Sweden
4 shared publications Hannu Kankaanranta
Krefting Research Centre Institute of Medicine, Sahlgrenska Academy, University of Gothenburg Gothenburg Sweden
4 shared publications- Daniil Lisik
Department of Public Health and Clinical Medicine, The OLIN and Sunderby Research Unit, Umeå University, Umeå, Sweden
3 shared publications - Helena Backman
Department of Public Health and Clinical Medicine, The OLIN and Sunderby Research Unit, Umeå University, Umeå, Sweden
3 shared publications Linda Ekerljung
Krefting Research Centre Institute of Medicine, Sahlgrenska Academy, University of Gothenburg Gothenburg Sweden
3 shared publications
Latest Publications
- Open Access
Late‐Onset Asthma Phenotypes by Onset Age: A Cluster Analysis in Swedish Population‐Based Cohorts
- Open Access
- 13 May 2025
- Published by Wiley
Late-onset asthma phenotypes by age of onset: a cluster analysis in Swedish population-based cohorts
Background: Asthma is a heterogeneous disease of phenotypes that differ by age at onset. At the same time, there is no consensus on the correct cut-off to determine late-onset asthma. This study aimed to characterize phenotypes of late-onset asthma in the general population using different minimum onset ages. Methods: We used survey and clinical data from two population-based studies. Cluster analysis with a novel deep clustering algorithm was performed in subjects with reported asthma onset at age ≥12 years ( n =3,103), ≥20 years ( n =2,431), and ≥40 years ( n =1,269) including data on anthropometrics/demographics, risk factors, asthma triggers, respiratory symptoms, asthma control, lung function, allergy, inflammation, and comorbidities. The clustering models were interpreted with decision trees, random forests, and a large language model. Potential risk factors, comorbidities, and clinical outcomes were evaluated descriptively. Results: Four clusters were identified in the ≥12 years group and three in the ≥20 years and ≥40 years groups. A partly/uncontrolled asthma cluster with dyspnea, cough, and cardiovascular comorbidity as well as an asthma cluster with broadly environmentally-triggered symptoms were identified in all age groups. A mild/moderate asthma cluster with allergic components was identified in the two younger onset age groups, while a mild asthma cluster was identified within the ≥12 years and ≥40 years groups. The clusters differed substantially by risk factors/exposures, comorbidity patterns, and clinical outcomes. Conclusions: Similar sets of asthma phenotypes arise across the course of adulthood, which are relatively easily identified. However, they are characterized by notable differences in clinical presentation, inflammation, comorbidities, and prognosis.
- 13 May 2025
- Published by Wiley
Open AccessLate-onset asthma phenotypes by age of onset: a cluster analysis in Swedish population-based cohorts
Background: Asthma is a heterogeneous disease of phenotypes that differ by age at onset. At the same time, there is no consensus on the correct cut-off to determine late-onset asthma. This study aimed to characterize phenotypes of late-onset asthma in the general population using different minimum onset ages. Methods: We used survey and clinical data from two population-based studies. Cluster analysis with a novel deep clustering algorithm was performed in subjects with reported asthma onset at age ≥12 years ( n =3,103), ≥20 years ( n =2,431), and ≥40 years ( n =1,269) including data on anthropometrics/demographics, risk factors, asthma triggers, respiratory symptoms, asthma control, lung function, allergy, inflammation, and comorbidities. The clustering models were interpreted with decision trees, random forests, and a large language model. Potential risk factors, comorbidities, and clinical outcomes were evaluated descriptively. Results: Four clusters were identified in the ≥12 years group and three in the ≥20 years and ≥40 years groups. A partly/uncontrolled asthma cluster with dyspnea, cough, and cardiovascular comorbidity as well as an asthma cluster with broadly environmentally-triggered symptoms were identified in all age groups. A mild/moderate asthma cluster with allergic components was identified in the two younger onset age groups, while a mild asthma cluster was identified within the ≥12 years and ≥40 years groups. The clusters differed substantially by risk factors/exposures, comorbidity patterns, and clinical outcomes. Conclusions: Similar sets of asthma phenotypes arise across the course of adulthood, which are relatively easily identified. However, they are characterized by notable differences in clinical presentation, inflammation, comorbidities, and prognosis.
- Open Access
Blood Eosinophil Reference Values and Determinants in a Representative Adult Population
Background: The use of blood eosinophil count (BEC) as a prognostic biomarker in the management of conditions such as asthma and chronic obstructive pulmonary disease (COPD) may be complicated by factors like atopy, age, sex, smoking, and comorbidities. Therefore, we aimed to produce reference values for BEC, considering age, asthma, COPD, and clinical allergy for the general adult population. Methods: The West Sweden Asthma Study constitutes a population-representative clinical epidemiological cohort of randomly selected adults in western Sweden. From this cohort, n =1,145 took part in clinical examinations, including e.g. skin prick testing, specific immunoglobulin E, and BEC. Results: The upper limit (95 th percentile) of BEC varied by age. It ranged between 400 to 500 cells/μL in the full sample, and from 300 to 400 cells/μL in subjects without asthma, COPD, and clinical allergy ( n =710). Sex, smoking, atopy, clinical allergy, obesity, asthma, COPD, diabetes, and hypertension were statistically significantly associated with higher BEC levels. However, only asthma and clinical allergy in the full sample, and obesity and diabetes in those without asthma, COPD, or clinical allergy, remained statistically significant in multiple regression analyses. Conclusion: In a population-representative sample, the upper limit of BEC in healthy adults ranged between 300 and 400 cells/μL, varying by age. Age, smoking, obesity, asthma, COPD, and clinical allergy influence BEC levels and should be considered in clinical interpretation. Clinical Implications: The upper limit of normal blood eosinophil count (BEC) in participants free from asthma, COPD, and clinical allergy ranged between 300 and 400 cells/μL depending on age. These results facilitate the interpretation of BEC in clinical practice. Capsule summary: The upper limit of normal blood eosinophil count (BEC) in healthy individuals ranged between 300 and 400 cells/μL depending on age. Determinants of BEC values include age, smoking, obesity, asthma, and clinical allergy. Support statement: The study was supported by the VBG Group Herman Krefting Foundation for Asthma and Allergy Research (Trollhättan, Sweden), Swedish Research Council (Stockholm, Sweden), the Swedish Heart-Lung Foundation (Stockholm, Sweden), the Swedish Asthma and Allergy Foundation (Stockholm, Sweden), Tampere Tuberculosis Foundation (Tampere, Finland), and ALF agreement (grant from the Swedish state under the agreement between the Swedish Government and the county councils, Sweden).
Open AccessBlood Eosinophil Reference Values and Determinants in a Representative Adult Population
Background: The use of blood eosinophil count (BEC) as a prognostic biomarker in the management of conditions such as asthma and chronic obstructive pulmonary disease (COPD) may be complicated by factors like atopy, age, sex, smoking, and comorbidities. Therefore, we aimed to produce reference values for BEC, considering age, asthma, COPD, and clinical allergy for the general adult population. Methods: The West Sweden Asthma Study constitutes a population-representative clinical epidemiological cohort of randomly selected adults in western Sweden. From this cohort, n =1,145 took part in clinical examinations, including e.g. skin prick testing, specific immunoglobulin E, and BEC. Results: The upper limit (95 th percentile) of BEC varied by age. It ranged between 400 to 500 cells/μL in the full sample, and from 300 to 400 cells/μL in subjects without asthma, COPD, and clinical allergy ( n =710). Sex, smoking, atopy, clinical allergy, obesity, asthma, COPD, diabetes, and hypertension were statistically significantly associated with higher BEC levels. However, only asthma and clinical allergy in the full sample, and obesity and diabetes in those without asthma, COPD, or clinical allergy, remained statistically significant in multiple regression analyses. Conclusion: In a population-representative sample, the upper limit of BEC in healthy adults ranged between 300 and 400 cells/μL, varying by age. Age, smoking, obesity, asthma, COPD, and clinical allergy influence BEC levels and should be considered in clinical interpretation. Clinical Implications: The upper limit of normal blood eosinophil count (BEC) in participants free from asthma, COPD, and clinical allergy ranged between 300 and 400 cells/μL depending on age. These results facilitate the interpretation of BEC in clinical practice. Capsule summary: The upper limit of normal blood eosinophil count (BEC) in healthy individuals ranged between 300 and 400 cells/μL depending on age. Determinants of BEC values include age, smoking, obesity, asthma, and clinical allergy. Support statement: The study was supported by the VBG Group Herman Krefting Foundation for Asthma and Allergy Research (Trollhättan, Sweden), Swedish Research Council (Stockholm, Sweden), the Swedish Heart-Lung Foundation (Stockholm, Sweden), the Swedish Asthma and Allergy Foundation (Stockholm, Sweden), Tampere Tuberculosis Foundation (Tampere, Finland), and ALF agreement (grant from the Swedish state under the agreement between the Swedish Government and the county councils, Sweden).
- Open Access
- 1 January 2021
- Published by Elsevier in Respiratory Medicine
- Vol. 176, 106250
The triad of current asthma, rhinitis and eczema is uncommon among adults: Prevalence, sensitization profiles, and risk factors
- 1 January 2021
- Published by Elsevier in Respiratory Medicine
- Vol. 176, 106250
Open AccessThe triad of current asthma, rhinitis and eczema is uncommon among adults: Prevalence, sensitization profiles, and risk factors
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64)
Asthma with and without rhinitis and eczema in adults: prevalence, sensitization profile, and risk factors
Background: The coexistence of asthma, rhinitis, and eczema has been studied in children, but data are lacking in adults. As new treatments emerge, epidemiological data on the coexistence of these conditions are needed. Aim: In a general adult population, we described the prevalence of concomitant asthma, rhinitis and eczema; compared prevalence between individuals sensitized and not sensitized to aeroallergens; and studied the risk factors for coexistence of the diseases. Methods: In the West Sweden Asthma Study, sensitization profile of 1103 randomly selected adults (16-75 years) was assessed with Phadiatop test. Participants answered clinical interviews on the presence of asthma, rhinitis and eczema. Results: In all study participants and in those with positive Phadiatop, 8% and 19% had concomitant asthma and rhinitis, but not eczema, respectively. Coexistence of the three conditions was 2% in all participants, but 6% in those with positive Phadiatop. Coexistence of the diseases did not differ by age or gender. Those with coexistence of asthma, rhinitis and eczema were most sensitized (78%), followed by those with asthma and rhinitis but not eczema (65%) and those with asthma and eczema but not rhinitis (40%), while those with asthma only had the least sensitization to aeroallergens (5%). Body mass index, exposure to gas, dust and fumes at work, and family history of asthma or allergy were associated with increased risk of coexistence of the three conditions. Conclusions: About 2% of adults have concomitant asthma, rhinitis, and eczema, and the proportion of allergic sensitization is high among them. Of sensitized adults, about 6% has coexistence of the three conditions.
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64)
Asthma with and without rhinitis and eczema in adults: prevalence, sensitization profile, and risk factors
Background: The coexistence of asthma, rhinitis, and eczema has been studied in children, but data are lacking in adults. As new treatments emerge, epidemiological data on the coexistence of these conditions are needed. Aim: In a general adult population, we described the prevalence of concomitant asthma, rhinitis and eczema; compared prevalence between individuals sensitized and not sensitized to aeroallergens; and studied the risk factors for coexistence of the diseases. Methods: In the West Sweden Asthma Study, sensitization profile of 1103 randomly selected adults (16-75 years) was assessed with Phadiatop test. Participants answered clinical interviews on the presence of asthma, rhinitis and eczema. Results: In all study participants and in those with positive Phadiatop, 8% and 19% had concomitant asthma and rhinitis, but not eczema, respectively. Coexistence of the three conditions was 2% in all participants, but 6% in those with positive Phadiatop. Coexistence of the diseases did not differ by age or gender. Those with coexistence of asthma, rhinitis and eczema were most sensitized (78%), followed by those with asthma and rhinitis but not eczema (65%) and those with asthma and eczema but not rhinitis (40%), while those with asthma only had the least sensitization to aeroallergens (5%). Body mass index, exposure to gas, dust and fumes at work, and family history of asthma or allergy were associated with increased risk of coexistence of the three conditions. Conclusions: About 2% of adults have concomitant asthma, rhinitis, and eczema, and the proportion of allergic sensitization is high among them. Of sensitized adults, about 6% has coexistence of the three conditions.
- 1 April 2018
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 49, 112-118
Small and large airway reactions to osmotic stimuli in asthma and chronic idiopathic cough
- 1 April 2018
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 49, 112-118
Small and large airway reactions to osmotic stimuli in asthma and chronic idiopathic cough
- Open Access
- 1 January 2015
- Published by Wiley in Clinical and Translational Allergy
- Vol. 5 (1) , 1-14
Use of a basophil activation test as a complementary diagnostic tool in the diagnosis of severe peanut allergy in adults
Background: Diagnosis of severe peanut allergy is difficult and delays in making an accurate diagnosis may place the patient at risk. Adults with a history of anaphylaxis must strictly avoid any contact with peanuts or products that may contain traces of peanuts. For these persons, conventional evaluations with skin prick testing (SPT) and IgE tests may not be sufficient to assess the risk of anaphylaxis. Therefore, we investigated whether the basophil activation test (BAT) could be used for the diagnosis of severe peanut allergy in adults. We compared the non‐invasive BAT with conventional laboratory diagnostic tests, including SPT and specific IgE to allergen extracts and components, for the diagnosis of severe peanut allergy.Methods: Forty‐seven persons with severe allergy to peanuts and a clinical diagnosis of anaphylaxis (PA‐group), 22 subjects with peanut sensitization (PS‐group) and 22 control (C‐group) subjects, all in the age range of 18–60 years, were recruited retrospectively and prospectively into the study. Thirty‐four patients with peanut allergy and 11 peanut‐sensitized patients were sensitized to soy, while 36 patients in the PA‐group and 20 patients in the PS‐group were sensitized to birch pollen. All the patients and control subjects were investigated with BAT and SPT for responses to peanut, soy and birch extracts and their serum samples were assayed for the presence of specific IgE to peanut, soy and birch extracts, as well as IgE to allergen components (ISAC).Results: In a multivariate factor analysis, severe peanut allergy (PA) was positively associated with SPT to peanut, IgE to peanut, BAT to peanut and IgE to rAra h 1, 2, 3 and 6 peanut components, as well as to soy components (nGly m 5 and nGly m 6). In contrast, peanut sensitization was positively associated with increased levels of IgE to rAra h 8, birch and birch‐related components. BAT‐detected reactivity to peanut was significantly higher in patients who had a history of severe allergy to peanuts, as compared with patients who were sensitized to peanuts (p < 0.001), and the receiver operating curve (ROC) analysis showed that BAT had high sensitivity and specificity for predicting severe peanut allergy, with a ROC area under the curve of 0.862. However, in the PA‐group, the BAT results for peanut correlated only weakly with the levels of IgE to rAra h 1, 2 and 3 and nAra h 6. Study limitations: oral provocation in the patients with a history of severe peanut allergy could not be performed to compare clinical reactivity with the BAT result due to ethical constraints. Neither was it possible to perform BAT with peanut recombinant allergens which were not available at the time the study commencedConclusions: BAT is useful in determining the severity of peanut allergy and may be used as a complementary diagnostic tool to ensure accurate diagnosis of severe peanut allergy in adults. Thus, it may reduce the need to subject these patients to further tests, including an open challenge with peanuts.
- 1 January 2015
- Published by Wiley in Clinical and Translational Allergy
- Vol. 5 (1) , 1-14
Open AccessUse of a basophil activation test as a complementary diagnostic tool in the diagnosis of severe peanut allergy in adults
Background: Diagnosis of severe peanut allergy is difficult and delays in making an accurate diagnosis may place the patient at risk. Adults with a history of anaphylaxis must strictly avoid any contact with peanuts or products that may contain traces of peanuts. For these persons, conventional evaluations with skin prick testing (SPT) and IgE tests may not be sufficient to assess the risk of anaphylaxis. Therefore, we investigated whether the basophil activation test (BAT) could be used for the diagnosis of severe peanut allergy in adults. We compared the non‐invasive BAT with conventional laboratory diagnostic tests, including SPT and specific IgE to allergen extracts and components, for the diagnosis of severe peanut allergy.Methods: Forty‐seven persons with severe allergy to peanuts and a clinical diagnosis of anaphylaxis (PA‐group), 22 subjects with peanut sensitization (PS‐group) and 22 control (C‐group) subjects, all in the age range of 18–60 years, were recruited retrospectively and prospectively into the study. Thirty‐four patients with peanut allergy and 11 peanut‐sensitized patients were sensitized to soy, while 36 patients in the PA‐group and 20 patients in the PS‐group were sensitized to birch pollen. All the patients and control subjects were investigated with BAT and SPT for responses to peanut, soy and birch extracts and their serum samples were assayed for the presence of specific IgE to peanut, soy and birch extracts, as well as IgE to allergen components (ISAC).Results: In a multivariate factor analysis, severe peanut allergy (PA) was positively associated with SPT to peanut, IgE to peanut, BAT to peanut and IgE to rAra h 1, 2, 3 and 6 peanut components, as well as to soy components (nGly m 5 and nGly m 6). In contrast, peanut sensitization was positively associated with increased levels of IgE to rAra h 8, birch and birch‐related components. BAT‐detected reactivity to peanut was significantly higher in patients who had a history of severe allergy to peanuts, as compared with patients who were sensitized to peanuts (p < 0.001), and the receiver operating curve (ROC) analysis showed that BAT had high sensitivity and specificity for predicting severe peanut allergy, with a ROC area under the curve of 0.862. However, in the PA‐group, the BAT results for peanut correlated only weakly with the levels of IgE to rAra h 1, 2 and 3 and nAra h 6. Study limitations: oral provocation in the patients with a history of severe peanut allergy could not be performed to compare clinical reactivity with the BAT result due to ethical constraints. Neither was it possible to perform BAT with peanut recombinant allergens which were not available at the time the study commencedConclusions: BAT is useful in determining the severity of peanut allergy and may be used as a complementary diagnostic tool to ensure accurate diagnosis of severe peanut allergy in adults. Thus, it may reduce the need to subject these patients to further tests, including an open challenge with peanuts.
- 1 September 2014
- Published by Elsevier in Respiratory Medicine
- Vol. 108 (9) , 1371-1376
Capsaicin cough threshold test in diagnostics
- 1 September 2014
- Published by Elsevier in Respiratory Medicine
- Vol. 108 (9) , 1371-1376
Capsaicin cough threshold test in diagnostics
- Open Access
- 1 January 2014
- Published by Wiley in Clinical and Translational Allergy
- Vol. 4 (1) , 19
Intestinal allergic inflammation in birch pollen allergic patients in relation to pollen season, IgE sensitization profile and gastrointestinal symptoms
Background: Birch pollen allergic patients frequently experience gastrointestinal upset accompanied by a local allergic inflammation in the small intestine especially during the pollen season. However, it is not known if the GI pathology is connected to the subjective symptoms of the patient. The objective of this study was to evaluate the immune pathology of the duodenal mucosa and the serum IgE antibody profiles in birch pollen allergic patients in relation to their gastrointestinal symptoms, during and outside the birch pollen season.Methods: Thirty‐two patients with birch pollen allergy and sixteen healthy controls were enrolled in the study. Twenty allergic patients had gastrointestinal symptoms and twelve did not. All participants underwent an allergy investigation and gastroscopy with duodenal biopsy. The duodenal biopsies were retrieved during the pollen season (May‐June) and off‐season (November‐March). The biopsies were immunostained for mast cells (IgE and tryptase), eosinophils, T cells (CD3), and dendritic cells (CD11c). Pollen‐specific IgE antibodies were determined by ImmunoCAP and component microarray (ISAC).Results: Patients in both pollen allergic groups showed similar degree of intestinal allergic inflammation during the pollen season regardless of gastrointestinal symptoms. The eosinophils, mast cells and dendritic cells were increased in the mucosa. Patients with gastrointestinal symptoms had significantly elevated IgE antibodies to birch (rBet v 1), hazelnut (rCor a 1), and apple (rMal d1) during the pollen season.Conclusions: Patients allergic to birch pollen have clear signs of an ongoing allergic inflammation in their intestinal mucosa, which is aggravated during the pollen season. The magnitude of the allergic intestinal inflammation is not associated with subjective gastrointestinal symptoms of the individual patient.
- 1 January 2014
- Published by Wiley in Clinical and Translational Allergy
- Vol. 4 (1) , 19
Open AccessIntestinal allergic inflammation in birch pollen allergic patients in relation to pollen season, IgE sensitization profile and gastrointestinal symptoms
Background: Birch pollen allergic patients frequently experience gastrointestinal upset accompanied by a local allergic inflammation in the small intestine especially during the pollen season. However, it is not known if the GI pathology is connected to the subjective symptoms of the patient. The objective of this study was to evaluate the immune pathology of the duodenal mucosa and the serum IgE antibody profiles in birch pollen allergic patients in relation to their gastrointestinal symptoms, during and outside the birch pollen season.Methods: Thirty‐two patients with birch pollen allergy and sixteen healthy controls were enrolled in the study. Twenty allergic patients had gastrointestinal symptoms and twelve did not. All participants underwent an allergy investigation and gastroscopy with duodenal biopsy. The duodenal biopsies were retrieved during the pollen season (May‐June) and off‐season (November‐March). The biopsies were immunostained for mast cells (IgE and tryptase), eosinophils, T cells (CD3), and dendritic cells (CD11c). Pollen‐specific IgE antibodies were determined by ImmunoCAP and component microarray (ISAC).Results: Patients in both pollen allergic groups showed similar degree of intestinal allergic inflammation during the pollen season regardless of gastrointestinal symptoms. The eosinophils, mast cells and dendritic cells were increased in the mucosa. Patients with gastrointestinal symptoms had significantly elevated IgE antibodies to birch (rBet v 1), hazelnut (rCor a 1), and apple (rMal d1) during the pollen season.Conclusions: Patients allergic to birch pollen have clear signs of an ongoing allergic inflammation in their intestinal mucosa, which is aggravated during the pollen season. The magnitude of the allergic intestinal inflammation is not associated with subjective gastrointestinal symptoms of the individual patient.
- Open Access
- 2 November 2010
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 6 (1) , 28
Quantitative expression of osteopontin in nasal mucosa of patients with allergic rhinitis: effects of pollen exposure and nasal glucocorticoid treatment
Osteopontin (OPN) is a multifunctional cytokine that has been primarily investigated in Th1 diseases. Recently, it has also been implicated in Th2-mediated allergic diseases, such as asthma. The expression of OPN in allergic rhinitis (AR) is currently unknown, as is the effect of intranasal glucocorticosteroids (GCs) on that expression. Subjects with AR were randomised to receive treatment with fluticasone propionate (FP) (n = 12) or a placebo (n = 16) over the grass pollen season and nasal biopsies were taken prior to, and during the season. OPN expression in the nasal mucosa was examined with immunohistochemistry. Healthy non-AR controls (n = 5) were used as a comparator. OPN expression was detected in epithelial cells, subepithelial infiltrating/inflammatory cells and cells lining the vessels and glands of all subjects. Comparison of the pre- and peak-pollen season biopsy sections in placebo treated patients revealed no increase in OPN expression during the grass pollen season (5.7% vs 6.4%). Treatment with a local glucocorticosteroid did not alter the expression of OPN during pollen exposure (6.2% vs 6.7%). OPN has been increasingly associated with the pathogenesis of various Th2-mediated diseases. However, our finding that the OPN expression in the nasal mucosa of AR patients is not significantly affected by allergen exposure and is comparable to that of the healthy controls, suggests that intracellular OPN is not directly involved in the pathogenesis of allergic rhinitis.
- 2 November 2010
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 6 (1) , 28
Open AccessQuantitative expression of osteopontin in nasal mucosa of patients with allergic rhinitis: effects of pollen exposure and nasal glucocorticoid treatment
Osteopontin (OPN) is a multifunctional cytokine that has been primarily investigated in Th1 diseases. Recently, it has also been implicated in Th2-mediated allergic diseases, such as asthma. The expression of OPN in allergic rhinitis (AR) is currently unknown, as is the effect of intranasal glucocorticosteroids (GCs) on that expression. Subjects with AR were randomised to receive treatment with fluticasone propionate (FP) (n = 12) or a placebo (n = 16) over the grass pollen season and nasal biopsies were taken prior to, and during the season. OPN expression in the nasal mucosa was examined with immunohistochemistry. Healthy non-AR controls (n = 5) were used as a comparator. OPN expression was detected in epithelial cells, subepithelial infiltrating/inflammatory cells and cells lining the vessels and glands of all subjects. Comparison of the pre- and peak-pollen season biopsy sections in placebo treated patients revealed no increase in OPN expression during the grass pollen season (5.7% vs 6.4%). Treatment with a local glucocorticosteroid did not alter the expression of OPN during pollen exposure (6.2% vs 6.7%). OPN has been increasingly associated with the pathogenesis of various Th2-mediated diseases. However, our finding that the OPN expression in the nasal mucosa of AR patients is not significantly affected by allergen exposure and is comparable to that of the healthy controls, suggests that intracellular OPN is not directly involved in the pathogenesis of allergic rhinitis.